HOLON, Israel, Oct. 24,
2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN)
(TASE: CGEN) a clinical-stage cancer immunotherapy company and a
pioneer in computational target discovery, today announced,
that the Company will release its third quarter 2023 financial
results on Tuesday, November 7, 2023,
before the U.S. financial markets open. Management will host
a conference call and webcast to review the results and provide a
corporate update at 8:30 AM ET.
As part of the update, management will discuss Compugen's data
that will have been presented at the Annual Meeting of the Society
for Immunotherapy of Cancer, being held on November 1-5, 2023.
To access the live conference call by telephone, please dial
1-866-744-5399 from the U.S.,
or +972-3-918-0644 internationally. The call will be available via
live webcast through Compugen's website, located at the following
link.
Following the live webcast, a replay will be available on the
Company's website.
About Compugen
Compugen is a clinical-stage therapeutic discovery and
development company utilizing its broadly applicable predictive
computational discovery capabilities to identify new drug targets
and biological pathways for developing cancer
immunotherapies. Compugen has developed two proprietary
product candidates: COM701, a potential first-in-class anti-PVRIG
antibody and COM902, a potential best-in-class antibody
targeting TIGIT for the treatment of solid tumors. Compugen also
has a clinical stage partnered program, rilvegostomig (previously
AZD2936), a PD-1/TIGIT bi-specific derived from COM902, in Phase 2
development by AstraZeneca through a license agreement for the
development of bi-specific and multi-specific antibodies. In
addition, the Company's therapeutic pipeline of
early-stage immuno-oncology programs consists of programs
aiming to address various mechanisms of immune resistance. The most
advanced program, COM503 is in IND enabling studies. COM503 is a
potential first-in-class, high affinity antibody which blocks the
interaction between IL-18 binding protein and IL-18, thereby
freeing natural IL-18 to inhibit cancer growth in the tumor
microenvironment. Compugen is headquartered in Israel, with offices in San Francisco, CA. Compugen's shares are
listed on Nasdaq and the Tel Aviv Stock Exchange under the
ticker symbol CGEN.
Company contact:
Yvonne Naughton, Ph.D.
Head of Investor Relations and Corporate Communications
Email: ir@cgen.com
Tel: +1 (628) 241-0071
View original
content:https://www.prnewswire.com/news-releases/compugen-to-release-third-quarter-2023-results-on-tuesday-november-7-2023-301965632.html
SOURCE Compugen Ltd.